(Q37329415)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Shan Lu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Susan Zolla-Pazner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Sandra Cohen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Abraham Pinter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Terri Wrin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Shixia Wang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

English

0 references

publication date

26 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

392

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

82-93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

3 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Vaccines: correlates of vaccine-induced immunity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Immunogenicity and protective efficacy of influenza vaccination

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

The antiviral activity of antibodies in vitro and in vivo.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

On the Specificity of Antibodies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736369

Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration

2 September 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Structural basis for coreceptor selectivity by the HIV type 1 V3 loop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Post-infection immunodeficiency virus control by neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Mechanisms contributing to the neutralization of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

7 January 2021

Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

7 January 2021

Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

7 January 2021

Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.039

7 January 2021

Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19632700

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1016/J.VIROL.2009.05.039

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

release_nhuyez2u45hktld4boed5gviuy

3 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nhuyez2u45hktld4boed5gviuy

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19632700%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference